Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis.


Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
12 2020
Historique:
received: 08 02 2020
revised: 03 06 2020
accepted: 12 06 2020
pubmed: 16 7 2020
medline: 12 10 2021
entrez: 16 7 2020
Statut: ppublish

Résumé

The purpose of this study was to evaluate the impact of breast size on long-term toxicity and cosmesis in patients with breast cancer treated with hypofractionated simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT). Patients with early stage breast cancer were treated with 3-week hypofractionated SIB-VMAT to the whole breast (40.5 Gy) and tumor bed (48 Gy). Two cohorts were identified: small/medium- (< 1000 cm From August 2010 to March 2017, a total of 1160 patients were treated; 831 had at least 2 years of follow-up and were analyzed. Treated skin area (TSA) receiving at least 20 Gy > 400 cm The TSA > 400 cm

Identifiants

pubmed: 32665192
pii: S1526-8209(20)30149-X
doi: 10.1016/j.clbc.2020.06.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-533

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Fiorenza De Rose (F)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Antonella Fogliata (A)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy. Electronic address: antonella.fogliata@humanitas.it.

Davide Franceschini (D)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Cristina Iftode (C)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Giuseppe R D'Agostino (GR)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Tiziana Comito (T)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Ciro Franzese (C)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Milan-Pieve Emanuele, Italy.

Lucia Di Brina (L)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Elena Clerici (E)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Mauro Loi (M)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Pierina Navarria (P)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Wolfgang Gatzemeier (W)

Breast Surgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Alberto Testori (A)

Breast Surgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Corrado Tinterri (C)

Breast Surgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Francesca Lobefalo (F)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Stefano Tomatis (S)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy.

Luca Cozzi (L)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Milan-Pieve Emanuele, Italy.

Marta Scorsetti (M)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center IRCCS, Milan-Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Milan-Pieve Emanuele, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH